Jacqueline S. M.
- Country
- Czechia
- Department
- N/A
Research Overview
- Phase 3 Randomized Study of Navtemadlin and Ruxolitinib Versus Placebo and Ruxolitinib in Myelofibrosis Patients with Suboptimal Ruxolitinib Response
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bleximenib, Venetoclax, and Azacitidine in Acute Myeloid Leukemia with KMT2A Rearrangements or NPM1 Mutations
- Efficacy and Safety of Rilzabrutinib in Adults with Warm Autoimmune Hemolytic Anemia: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 54 of 204 partner sites.
Specializations
Hematologic Disorders
The investigator specializes in treating myelofibrosis, including both primary and secondary forms of this hematologic condition. Their research encompasses therapeutic approaches for post-Polycythemia Vera and post-Essential Thrombocythemia manifestations.
- Primary Myelofibrosis Management
- Secondary Myelofibrosis Treatment
Their therapeutic focus includes innovative combination approaches using targeted therapies for myeloproliferative disorders.
Clinical Outcomes
The investigator focuses on measuring therapeutic efficacy through key clinical parameters including spleen volume reduction and symptom score assessment in hematologic conditions.
- Spleen Response Evaluation
- Symptom Burden Assessment
Their work emphasizes quantifiable clinical outcomes in the treatment of myelofibrosis patients.
Therapeutic Innovation
The investigator explores novel therapeutic combinations in myeloproliferative neoplasms, evaluating emerging treatment strategies for patients with myelofibrosis.
- Combination Therapy Approaches
- Novel Treatment Strategies
Their research interests include the development of targeted therapeutic interventions for hematologic malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.